23
ALL23
Timber PharmaceuticalsYear
23
ALL2
20242
20238
20225
20216
2020DEALS // DEV.
23
ALL7
Deals16
DevelopmentsCountry
23
ALL1
NEW ZEALAND22
U.S.A23
ALL1
AFT Pharmaceuticals1
BioPharmX1
H.C. Wainwright & Co.2
Leo Pharma16
Not Applicable1
Timber Pharmaceuticals1
U.S. Food & Drug AdministrationTherapeutic Area
23
ALL4
Dermatology18
Genetic Disease1
ImmunologyStudy Phase
23
ALL19
Phase III3
Phase II1
IND EnablingDeal Type
7
ALL2
Acquisition1
Funding1
Licensing Agreement2
Merger1
Public OfferingProduct Type
23
ALL23
Small moleculeDosage Form
21
ALL9
Ointment4
Topical1
Topical Gel7
Topical OintmentLead Product
23
ALL20
Isotretinoin1
Minocycline Hydrochloride1
Sirolimus1
SitaxentanTarget
18
ALL1
Endothelin Receptor16
RAR1
mTORLead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Timber Pharma Updates TMB-001 Development For Congenital Ichthyosis
Details : MB-001 is an investigational topical ointment formulation of isotretinoin for the potential treatment of patients with moderate to severe congenital ichthyosis.
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Not Applicable
August 21, 2024
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Leo Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
LEO Pharma Finalizes Acquisition of Key Assets from Timber Pharmaceuticals
Details : LEO expands its pipeline by acquiring TMB-001, an investigational topical reformulation of isotretinoin, which is currently only available orally in the U.S.
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : Isotretinoin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Leo Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Leo Pharma
Deal Size : $36.0 million
Deal Type : Acquisition
LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical
Details : Through the acquisition, LEO gains rights to establish TMB-001, topical isotretinoin in Timber's patented IPEG™ delivery system, as the standard of care in the treatment of congenital ichthyosis, a devastating, rare disease.
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : $14.0 million
August 21, 2023
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Leo Pharma
Deal Size : $36.0 million
Deal Type : Acquisition
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TMB-001 (isotretinoin) inhibits sebaceous gland function and keratinization at pharmacologic doses. It is being developed for the treatment of X-Linked recessive ichthyosis.
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Not Applicable
February 24, 2023
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TMB-001 is a topical isotretinoin, formulated using IPEG™ delivery system, in development for the treatment of moderate to severe forms of congenital ichthyosis.
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TMB-001 is a topical isotretinoin, formulated using the Company’s patented IPEG™ delivery system, in development for the treatment of moderate to severe forms of congenital ichthyosis (CI) including ARCI and X-linked recessive ichthyosis (XLRI).
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TMB-001 is a topical isotretinoin formulation in development based on the Company’s patented IPEG™ delivery system for the treatment of moderate to severe forms of congenital ichthyosis (CI).
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co.
Deal Size : $8.0 million
Deal Type : Public Offering
Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering
Details : The Company intends to use the net proceeds from this offering for research and development, including clinical trials of TMB-001 having isotretinoin, working capital and general corporate purposes.
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Undisclosed
August 08, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co.
Deal Size : $8.0 million
Deal Type : Public Offering
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TMB-001 0.05%, a topical isotretinoin formulated using patented IPEG™ delivery system, for treatment of moderate to severe forms of congenital ichthyosis.
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the Phase 2b CONTROL study, treatment with TMB-001 (Isotretinoin) demonstrated a clinically meaningful reduction in targeted and overall severity of CI along with a favorable safety profile.
Product Name : TMB-001
Product Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2022
Lead Product(s) : Isotretinoin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable